Propanc Biopharma announced new preclinical data demonstrating that its lead drug candidate, PRP, can reprogram chemotherapy-resistant pancreatic cancer cells, reducing tumor growth and metastatic behavior. The drug works by reversing epithelial-mesenchymal transition (EMT) and enhancing cancer cell vulnerability to chemotherapy. PRP's unique mechanism targets cancer stem cells and fibrosis, complementing existing RAS inhibitors. The company plans to start a Phase 1b first-in-human trial in early 2027 to test PRP in advanced solid tumors, including pancreatic cancer.
Propanc Biopharma's new data on PRP and pancreatic cancer offers context for readers interested in health-sector stocks. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 26, 2026 19:02 WIB: out of 150 priced US health stocks, 78 rose and 48 fell. Notable movers include ABEO at USD 4.54 with a 3.18% increase, BNTX at USD 85.50 down 2.97%, and CLPT at USD 9.38 up 2.63%.
Senseonics Holdings has begun the first human clinical trial of Freedom, a next-generation continuous glucose monitoring (CGM) system designed without an external on-body transmitter. This implantable device communicates directly with mobile devices ...
Stryker Corporation has finalized its acquisition of ZuriMED, incorporating the FiberLocker System into its Sports Medicine offerings. This technology enhances rotator cuff repair by improving biomechanical strength, addressing a key clinical need. T...
Kratos Defense & Security Solutions announced it will release its third quarter 2026 financial results after market close on November 5, 2026. The company will hold a conference call at 2:00 p.m. Pacific Time to discuss its operations and financial p...
FOREWARN, a safety solutions provider for real estate professionals, introduced Community Alerts, a new feature that allows agents to flag phone numbers after concerning interactions. This alert is instantly shared across its network of over 443,000 ...
Franklin Electric Co., Inc. announced a quarterly cash dividend of $0.28 per share, payable on November 19, 2026, to shareholders of record as of November 5, 2026. This dividend reflects the company's ongoing commitment to returning value to its shar...
